DCCC Radiotherapy Annual meeting October 24-25, 2019.
Conference center ‘Sund og Skov’, Oddevejen 8, 5500 Middelfart

Thursday October 24

09:00-09:30  Arrival and coffee

09:30-10:00  Welcome and news from DCCC Radiotherapy - Cai, Jesper, and Stine.
Activities
Budget
Objectives

10:00-10:30  National infrastructures – plenary presentations from work groups
• WP 10 – Experimental radiation oncology
• WP 11 – National dosimetry lab
• WP 12 – National radiotherapy imaging data bank
• WP 13 – Clinical trials quality assurance platform
• WP 14 – Bioinformatics and modelling core
• WP 15 – Education and knowledge dissemination

Discussion of ongoing projects and future initiatives.

11:30-11:50  Translational research focus areas – plenary presentations from work groups, round 1.
• WP1 – Molecular biomarkers
• WP3 – Immuno-radiotherapy
• WP5 – Treatment planning and automation
• WP6 – Epidemiology, patterns of care, phase IV

11:50-12:45  Lunch

12:45-13:45  Second break-out session – Translational research focus areas, round 1.
Discussion of ongoing projects and future initiatives.
13:45-15:15  Plenary thematic session on AI:

*Invited keynote lecture:* ‘Artificial Intelligence and Deep Learning for Medical Imaging’, by Ole Winther, Professor of Genomic Bioinformatics, Copenhagen University Hospital.

Presentations of AI related projects in Danish RT Centers, including deep learning for segmentation, radiomics for outcome prediction, Ethos application, and more.

15:15-15:45  Coffee

15:45-16:15  Flash talks session 1, plenary

- Maja Sharma, Aarhus University Hospital: Morbidity after radiation therapy for sinonasal cancer
- Marie Tvilum, Aarhus University Hospital: Optimal Individual Treatment Strategy for Every Non-small Cell Lung Cancer Patient
- Jintao Ren, Aarhus University Hospital: Automatic head and neck tumor delineation with deep learning
- Jens Petersen, University of Copenhagen & Rigshospitalet: Deep learning based-image annotation methods for risk modelling: towards automation for registry-based complication modeling
- Marie Louise Milo, Aarhus University Hospital: Risk of radiotherapy induced heart disease in women treated for early stage breast cancer
- Stine Rauff Søndergaard, Vejle Sygehus: Shared Decision Making for breast cancer patients who are offered adjuvant radiotherapy.
- Anna Cecilie Lefevre, Aarhus University Hospital: Prognostic markers in squamous cell carcinoma of the anus.
16:15-17:25 Plenary presentations from the intervention protocol work groups.
- IP1 – Children
- IP2 – Brain
- IP3 – Eye
- IP4 – Head and neck
- IP5 – Lung
- IP6 – Breast
- IP7 – Upper gastrointestinal

18:30 Dinner

Friday October 25

07:00-07:30 Morning run

07:30-08:30 Breakfast

08:30-09:10 Flash talks session 2, plenary
- Casper Muurholm, Aarhus University Hospital: Experimental validation of real-time dose reconstruction during dynamic treatments in a pelvis phantom with rotating tumor insert
- Simon Jensen, Aarhus University: Motion and deformation in 3D dosimetry
- Kristian Hastoft Jensen, Copenhagen University Hospital, Rigshospitalet: Early mortality following radical radiotherapy in patients with head and neck cancer
- Cathrine Bang Overgaard, Aarhus University Hospital: Preclinical RBE for normal tissue damage established in in vivo model
- Jacob Johansen, Aarhus University Hospital: Multi-centre study of real-time in vivo dosimetry for brachytherapy
- Signe Winther Hasler, Odense University Hospital: National Interdisciplinary Network for Quality Assurance of MR images in radiotherapy (NIMBUS)
- Raul Argota Perez, Aarhus University Hospital: Individualized robustness in treatment planning for head and neck proton radiotherapy
- Esben Worm, Aarhus University Hospital: Proton therapy of tumors in the liver: Prescription strategy, motion and interplay effects.
- Laura Toussaint, Aarhus University Hospital / DCPT: Voxel-based analysis of brain MRI changes after radiation therapy for pediatric central nervous system tumors
- Sofie Rahbek, DTU and OUH: Title tbc
09:10-09:50  Plenary presentations from the intervention protocol work groups.
  - IP8 – Liver – gall bladder
  - IP9 – Pancreas
  - IP10 – Colorectal
  - IP11 – Anal canal

09:50-10:10  Coffee

10:10-10:30  Translational research focus areas – plenary presentations from work groups, round 2.
  - WP2 – Imaging biomarkers
  - WP4 – Adaptive radiotherapy
  - WP7 – Late effects and PROM
  - WP8 – Model-based selection

10:30-11:30  Third break-out session – Translational research focus areas, round 2.
  Discussion of ongoing projects and future initiatives.

11:30-12:10  Plenary presentations from the intervention protocol work groups.
  - IP12 – Gynaecology
  - IP13 – Prostate
  - IP14 – Sarcoma
  - IP15 – Oligometastatic disease

12:10-12:30  Wrap up – Cai, Jesper, and Stine.

12:30-13:15  Lunch

13:15-15:00  Work group meetings – option for meetings within and across workgroups.
DCCC Radiotherapy

Work packages (WP)
- WP1 Molecular biomarkers
- WP2 Imaging biomarkers
- WP3 Immuno-radiotherapy
- WP4 Adaptive radiotherapy
- WP5 Dose planning and automation
- WP6 Epidemiology, patterns of care, phase IV
- WP7 Late effects and PROM
- WP8 Model-based selection
- WP10 Experimental Radiation Oncology
- WP11 National dosimetry laboratory
- WP12 National radiotherapy imaging bank
- WP13 Clinical trials quality assurance platform
- WP14 Biostatistics and modelling core
- WP15 Education and knowledge dissemination

Interventional protocols (IP)
- IP1 Children – DAPHO
- IP2 Brain – DNOG
- IP3 Eye – DDOG
- IP4 Head and neck – DANVAC
- IP5 Lung – DOLG
- IP6 Breast – DBCG
- IP7 Upper gastrointestinal – DCCV
- IP8 Liver – gill bladder – DDDCO
- IP9 Pancreas – DPG
- IP10 Colorectal – DCG
- IP11 Anal canal – DACG
- IP12 Gynaecology – DDCG
- IP13 Prostate – DAPOCA
- IP14 Sarcoma – DG
- IP15 Oligometastatic disease

DCCC Radiotherapy Annual meeting 2019

Steering committee
Ivan Vagelius, Claus Behrens (chair), Carsten Brink, Jens Overgaard, Morten Høy, Denti Leurizzen, Jimmi Sandergaard, Kenneth Hoff, John Peter Mortensen

National Research Center
Col Group, Jesper Erlesen
Stone Kommemann, Louise Leursen

Clinical Trials Danish Radiotherapy Cancer Group (DCG)